Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Weir

Showing results (471-480 of 499) with videos related to

Pageof 50
Sort By:
Circulation|October 8, 2019
High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial InfarctionAndrew R Chapman, Philip D Adamson, Anoop S V Shah, et al.
Molecular Carcinogenesis|October 11, 2022
Doublecortin-like kinase 1 is a therapeutic target in squamous cell carcinomaDavid Standing, Levi Arnold, Prasad Dandawate, et al.
Nature Communications|December 22, 2019
scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapyJennifer Karin Ocasio, Benjamin Babcock, Daniel Malawsky, et al.
American Journal of Hematology|November 26, 2013
Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignanciesMark D Minden, Donna E Hogge, Scott J Weir, et al.
BMJ Open|September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosisPeter Connick, Floriana De Angelis, Richard A Parker, et al.
The Lancet. Neurology|January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trialJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
Journal of the American College of Cardiology|October 19, 2019
Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary SyndromeKuan Ken Lee, Amy V Ferry, Atul Anand, et al.
Gastroenterology|December 2, 2019
Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in MicePrasad Dandawate, Gaurav Kaushik, Chandrayee Ghosh, et al.
Circulation|March 23, 2021
High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled TrialAtul Anand, Kuan Ken Lee, Andrew R Chapman, et al.
Intensive Care Medicine|October 7, 2018
Early PREdiction of sepsis using leukocyte surface biomarkers: the ExPRES-sepsis cohort studyManu Shankar-Hari, Deepankar Datta, Julie Wilson, et al.
Pageof 50

Showing results (471-480 of 499) with videos related to

Sort By:
Pageof 50
Circulation|October 8, 2019
High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial InfarctionAndrew R Chapman, Philip D Adamson, Anoop S V Shah, et al.
Molecular Carcinogenesis|October 11, 2022
Doublecortin-like kinase 1 is a therapeutic target in squamous cell carcinomaDavid Standing, Levi Arnold, Prasad Dandawate, et al.
Nature Communications|December 22, 2019
scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapyJennifer Karin Ocasio, Benjamin Babcock, Daniel Malawsky, et al.
American Journal of Hematology|November 26, 2013
Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignanciesMark D Minden, Donna E Hogge, Scott J Weir, et al.
BMJ Open|September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosisPeter Connick, Floriana De Angelis, Richard A Parker, et al.
The Lancet. Neurology|January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trialJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
Journal of the American College of Cardiology|October 19, 2019
Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary SyndromeKuan Ken Lee, Amy V Ferry, Atul Anand, et al.
Gastroenterology|December 2, 2019
Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in MicePrasad Dandawate, Gaurav Kaushik, Chandrayee Ghosh, et al.
Circulation|March 23, 2021
High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled TrialAtul Anand, Kuan Ken Lee, Andrew R Chapman, et al.
Intensive Care Medicine|October 7, 2018
Early PREdiction of sepsis using leukocyte surface biomarkers: the ExPRES-sepsis cohort studyManu Shankar-Hari, Deepankar Datta, Julie Wilson, et al.
Pageof 50